<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774315</url>
  </required_header>
  <id_info>
    <org_study_id>18-0850</org_study_id>
    <nct_id>NCT04774315</nct_id>
  </id_info>
  <brief_title>Molecular Endotypes of Chronic Idiopathic Urticaria</brief_title>
  <official_title>Molecular Endotypes of Chronic Idiopathic Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU)&#xD;
      respond to treatment with omalizumab (Xolair). It will test people before they receive&#xD;
      treatment with omalizumab as part of standard of care, to see if there are differences in&#xD;
      their blood and skin that can predict who responds to treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responders</measure>
    <time_frame>Week 16</time_frame>
    <description>The number of participants who meet the definition of &quot;Responder&quot; to omalizumab. &quot;Responders&quot; are defined as having a UAS7 of 6 or less after 16 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline expression of innate immune markers</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline expression of innate immune markers in peripheral blood between eventual responders and nonresponders to omalizumab. 5 significant markers will be reported. Results will be stratified between groups determined by the pre-specified arms and by the classification of participants as responders versus non-responders to omalizumab.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Chronic Urticaria, Idiopathic</condition>
  <arm_group>
    <arm_group_label>Omalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>omalizumab 300mg SQ every 4 weeks as part of standard of care</description>
    <arm_group_label>Omalizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CIU as defined as frequent urticarial lesions for â‰¥ 6 weeks&#xD;
&#xD;
          -  Symptoms not controlled with standard dose antihistamines (loratadine 10mg daily,&#xD;
             desloratadine 5mg daily, fexofenadine 180mg daily, cetirizine 10mg daily, or&#xD;
             levocetirizine 5mg daily)&#xD;
&#xD;
          -  Planned initiation of treatment with omalizumab (Xolair) as part of standard of care&#xD;
             for antihistamine-refractory urticaria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of immunomodulatory drugs in the past 1 month prior to beginning the study&#xD;
&#xD;
          -  Use of systemic steroids in the past 1 month prior to beginning the study&#xD;
&#xD;
          -  Use of omalizumab in the past 3 months prior to beginning the study&#xD;
&#xD;
          -  Use of any investigational agent in the past 30 days&#xD;
&#xD;
          -  Untreated intercurrent illness&#xD;
&#xD;
          -  Severe Asthma&#xD;
&#xD;
          -  Primary diagnosis of flushing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny Stitt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Stitt, M.D.</last_name>
    <phone>303-724-1111</phone>
    <email>clinicalresearchsupportcenter@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anschutz</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jenny Stitt</last_name>
      <phone>303-724-7205</phone>
      <email>jenny.stitt@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Jenny Stitt, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

